Using T-cell repertoire profiles as predictor in a primary mucosal melanoma
| Autor: | Yu‐Ming Liao, Yun Yen, Gong‐Yau Lan, Wei Chiao Chang, Che‐Mai Chang |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Pathology medicine.medical_specialty Medicine (General) medicine.medical_treatment Medicine (miscellaneous) Pembrolizumab Stereotactic radiation therapy Letter to Editor 03 medical and health sciences 0302 clinical medicine R5-920 medicine Chemotherapy medicine.diagnostic_test business.industry Melanoma Mucosal melanoma Magnetic resonance imaging Immunotherapy medicine.disease Radiation therapy 030104 developmental biology 030220 oncology & carcinogenesis Molecular Medicine business |
| Zdroj: | Clinical and Translational Medicine, Vol 10, Iss 4, Pp n/a-n/a (2020) Clinical and Translational Medicine |
| Popis: | Dear Editor, Primary mucosal melanoma is a rare subtype of melanoma that carries poor prognosis. Traditional treatment options of mucosal melanoma are surgery, radiation, and chemotherapy; but the overall survival remains low.1 Cytotoxic T‐lymphocyte associated protein 4 (CLTA‐4) and programmed cell death protein 1 (PD‐1), both inhibitory immune checkpoints commonly seen on activated T cells, have been found to be promising targets for treatment of advanced cancers.2 However, the efficacy and response to immunotherapy in mucosal melanoma remains unknown. Herein, we report a case involving a patient, who was a 70‐year‐old male and referred to Taipei Medical University Hospital with confirmed diagnosis of mucosa melanoma over hard plate of mouth. The patient was admitted and subjected to anti‐PD‐1 immunotherapy (pembrolizumab 200 mg every 3 weeks) (Figure 1A). Serial imaging of primary malignant melanoma of the hard palate showed that the tumor size gradually decreased after treatment with pembrolizumab, suggesting partial response/stable disease secondary to continuous immunotherapy (Figure 1B). However, after seventh cycle of treatment, magnetic resonance imaging (MRI) revealed enlarged previous known metastatic lesions and new tumor nodules in brain (Figure 1B). The patient received stereotactic radiation therapy before treatment cycle 14 (Figure 1A). Although the primary metastatic brain lesions were smaller and stationary after radiotherapy, the following brain MRI displayed several hyperdensity masses in the right frontal lobe with perifocal edema and mild mass effect (Figure 1B). Subsequently, patient suffered from infection and respiratory distress and died 2 months after 17th cycle of pembrolizumab therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|